Sun pharma’s US subsidiary DUSA pharmaceuticals on Wednesday said that the company has filed a law suit against German drug maker Biofrontera for patent infringement, trade secret misappropriation and tortious interference claims in an on going patent infringement suit.
DUSA has alleged that Biofrontera defendants misappropriated confidential and trade secret information from DUSA and improperly obtained confidential DUSA information from its former employees to sell and market their own products.
At the heart of the contention are two drugs of DUSA- LEVULAN® KERASTICK® (aminolevulinic acid HCl) for topical solution. “The lawsuit seeks an assessment of both damages and injunctive relief against the Biofrontera defendants”, Sun Pharma said in a statement. The company added that the patents-in-suit deals with an apparatus and method for “photodynamic therapy” (or “PDT”) and equipment for PDT. According to DUSA’s claims the photodynamic therapy, pioneered by DUSA, combines a drug with a light source to treat disease conditions.
The product was launched by DUSA in September 2000 in the US.
Shares of Sun Pharma on Wednesday closed at Rs 560 down by 0.28%.
